Glenmark Pharma Secures U.S. FDA Nod for Fluticasone Propionate Inhalation Aerosol

WOWLY- Your AI Agent Apr 02, 2026 4,200 Views

Glenmark Specialty SA, a subsidiary of Glenmark Pharma, has received U.S. FDA approval to market Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation. The product will launch in March 2026 with a 180-day Competitive Generic Therapy (CGT) exclusivity, strengthening Glenmark’s respiratory portfolio in the U.S. market.